218 related articles for article (PubMed ID: 25949459)
1. Individualizing anaemia therapy.
de Francisco AL
NDT Plus; 2010 Dec; 3(6):519-26. PubMed ID: 25949459
[TBL] [Abstract][Full Text] [Related]
2. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
[TBL] [Abstract][Full Text] [Related]
3. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
4. Anaemia management and mortality risk in chronic kidney disease.
Hörl WH
Nat Rev Nephrol; 2013 May; 9(5):291-301. PubMed ID: 23438972
[TBL] [Abstract][Full Text] [Related]
5. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
Lines SW; Lindley EJ; Tattersall JE; Wright MJ
Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial.
Macdougall IC
Trials; 2007 Nov; 8():35. PubMed ID: 17999759
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
[TBL] [Abstract][Full Text] [Related]
8. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
Coronado Daza J; Martí-Carvajal AJ; Ariza García A; Rodelo Ceballos J; Yomayusa González N; Páez-Canro C; Loza Munárriz C; Urrútia G
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011122. PubMed ID: 26671531
[TBL] [Abstract][Full Text] [Related]
9. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
11. Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents.
de Francisco ALM; Piñera C
Contrib Nephrol; 2011; 171():248-254. PubMed ID: 21625120
[TBL] [Abstract][Full Text] [Related]
12. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients.
Ngo K; Kotecha D; Walters JA; Manzano L; Palazzuoli A; van Veldhuisen DJ; Flather M
Cochrane Database Syst Rev; 2010 Jan; (1):CD007613. PubMed ID: 20091643
[TBL] [Abstract][Full Text] [Related]
14. Use of the esa resistance index to guide dosing for anaemia management.
Ross EA; Paugh-Miller JL; Wen X; Nappo RW
J Ren Care; 2020 Dec; 46(4):216-221. PubMed ID: 32219971
[TBL] [Abstract][Full Text] [Related]
15. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
[TBL] [Abstract][Full Text] [Related]
16. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis.
Evans M; Bower H; Cockburn E; Jacobson SH; Barany P; Carrero JJ
Clin Kidney J; 2020 Oct; 13(5):821-827. PubMed ID: 33123358
[TBL] [Abstract][Full Text] [Related]
17. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.
Kainz A; Mayer B; Kramar R; Oberbauer R
Nephrol Dial Transplant; 2010 Nov; 25(11):3701-6. PubMed ID: 20507852
[TBL] [Abstract][Full Text] [Related]
18. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
[TBL] [Abstract][Full Text] [Related]
19. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
Locatelli F; Aljama P; Canaud B; Covic A; De Francisco A; Macdougall IC; Wiecek A; Vanholder R;
Nephrol Dial Transplant; 2010 Sep; 25(9):2846-50. PubMed ID: 20591813
[TBL] [Abstract][Full Text] [Related]
20. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
